SCM
FULC icon

Suvretta Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Suvretta Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Sell
3,680,921
-2,880,190
-44% -$17.5M 0.25% 52
2026
Q1 		$50.3M Hold
6,561,111
– – 1.29% 31
2025
Q4 		$74.2M Buy
6,561,111
+1,180,111
+22% +$12M 1.52% 29
2025
Q3 		$49.5M Buy
5,381,000
+298,100
+6% +$2.16M 1.27% 32
2025
Q2 		$35M Buy
5,082,900
+15,506
+0.3% +$82.9K 1.05% 33
2025
Q1 		$14.6M Buy
5,067,394
+1,728,928
+52% +$6.35M 0.54% 49
2024
Q4 		$15.7M Buy
3,338,466
+2,155,675
+182% +$7.95M 0.53% 49
2024
Q3 		$4.22M Sell
1,182,791
-1,358,255
-53% -$10.1M 0.14% 66
2024
Q2 		$15.8M Sell
2,541,046
-307,440
-11% -$2.33M 0.58% 43
2024
Q1 		$26.9M Sell
2,848,486
-2,670,395
-48% -$23.8M 1% 34
2023
Q4 		$37.3M Sell
5,518,881
-200,000
-3% -$887K 1.68% 21
2023
Q3 		$25.4M Hold
5,718,881
– – 1.37% 24
2023
Q2 		$18.9M Buy
5,718,881
+541,171
+10% +$1.59M 1.01% 35
2023
Q1 		$14.8M Buy
5,177,710
+902,907
+21% +$8.09M 0.62% 45
2022
Q4 		$31.1M Buy
4,274,803
+746,803
+21% +$4.87M 1.31% 31
2022
Q3 		$28.5M Buy
3,528,000
+172,376
+5% +$1.23M 1.19% 32
2022
Q2 		$16.4M Buy
3,355,624
+742,212
+28% +$7.25M 0.63% 49
2022
Q1 		$61.8M Buy
2,613,412
+237,841
+10% +$3.37M 1.89% 23
2021
Q4 		$42M Buy
2,375,571
+433,602
+22% +$8.59M 0.81% 35
2021
Q3 		$54.8M Buy
1,941,969
+314,525
+19% +$5.96M 0.92% 34
2021
Q2 		$17.1M Buy
1,627,444
+101,559
+7% +$1.03M 0.26% 65
2021
Q1 		$18M Buy
+1,525,885
New +$18.9M 0.27% 61

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Suvretta Capital Management's FULC Position: Q2 2026 in Review

Suvretta Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 44% in Q2 2026, selling an estimated $17.5M and leaving 3,680,921 shares worth $13.5M. The position accounts for 0.25% of the portfolio, ranked #52.

Suvretta Capital Management first reported a position in FULC in Q1 2021 and has held it in 22 quarters since. The position peaked at $74.2M in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Suvretta Capital Management held 3,680,921 shares of Fulcrum Therapeutics worth $13.5M as of Q2 2026.
  • Suvretta Capital Management sold 2,880,190 Fulcrum Therapeutics shares in Q2 2026, an estimated $17.5M.
  • Fulcrum Therapeutics made up 0.25% of Suvretta Capital Management's portfolio in Q2 2026, its #52 holding.
  • Suvretta Capital Management first reported a position in Fulcrum Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Suvretta Capital Management's Fulcrum Therapeutics position peaked at $74.2M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.